MA43816A - Protéines de liaison inductibles et méthodes d'utilisation - Google Patents

Protéines de liaison inductibles et méthodes d'utilisation

Info

Publication number: MA43816A
Authority: MA; Morocco
Prior art keywords: inductible; methods; binding proteins; proteins; binding
Prior art date: 2016-03-08

Application number

MA043816A

Other languages

English (en)

Inventor

Patrick Baeuerle

Robert B Dubridge

Luke Evnin

Jeanmarie Guenot

Anand Panchal

Maia Vinogradova

Holger Wesche

Original Assignee

Maverick Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-08

Filing date

2017-03-08

Publication date

2018-11-28

2017-03-08 Application filed by Maverick Therapeutics Inc filed Critical Maverick Therapeutics Inc

2018-11-28 Publication of MA43816A publication Critical patent/MA43816A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Cell Biology (AREA)
Transplantation (AREA)
Virology (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA043816A 2016-03-08 2017-03-08 Protéines de liaison inductibles et méthodes d'utilisation MA43816A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662305092P	2016-03-08	2016-03-08

Publications (1)

Publication Number	Publication Date
MA43816A true MA43816A (fr)	2018-11-28

Family

ID=59789722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA043816A MA43816A (fr)	2016-03-08	2017-03-08	Protéines de liaison inductibles et méthodes d'utilisation

Country Status (14)

Country	Link
US (1)	US20180134789A1 (fr)
EP (1)	EP3426689A4 (fr)
JP (3)	JP7195927B2 (fr)
KR (2)	KR102501921B1 (fr)
CN (1)	CN109071667A (fr)
AU (1)	AU2017229687A1 (fr)
BR (1)	BR112018068189A2 (fr)
CA (1)	CA3016165A1 (fr)
IL (1)	IL261432B2 (fr)
MA (1)	MA43816A (fr)
MX (1)	MX2018010824A (fr)
SG (1)	SG11201807548SA (fr)
TW (2)	TW202302631A (fr)
WO (1)	WO2017156178A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107849148B (zh)	2015-05-21	2023-09-19	哈普恩治疗公司	三特异性结合蛋白质及使用方法
WO2017087789A1 (fr)	2015-11-19	2017-05-26	Revitope Limited	Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables
US12128102B2 (en)	2016-03-08	2024-10-29	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
LT3461261T (lt)	2016-05-20	2025-08-25	Harpoon Therapeutics, Inc.	Vienos grandinės kintamo fragmento cd3 surišantys baltymai
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
US10100106B2 (en)	2016-05-20	2018-10-16	Harpoon Therapeutics, Inc.	Single domain serum albumin binding protein
ES2875959T3 (es)	2016-10-07	2021-11-11	Tcr2 Therapeutics Inc	Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
CA3044729A1 (fr)	2016-11-23	2018-05-31	Harpoon Therapeutics, Inc.	Proteines trispecifiques ciblang le psma et procedes d'utilisation
WO2018098354A1 (fr)	2016-11-23	2018-05-31	Harpoon Therapeutics, Inc.	Protéine de liaison à l'antigène membranaire spécifique de la prostate
EP3589662A4 (fr)	2017-02-28	2020-12-30	Harpoon Therapeutics, Inc.	Protéine monovalente inductible de fixation d' antigène
WO2018160671A1 (fr) *	2017-02-28	2018-09-07	Harpoon Therapeutics, Inc.	Inhibiteurs de point de contrôle ciblés et méthodes d'utilisation
US20200115461A1 (en) *	2017-05-03	2020-04-16	Harpoon Therapeutics, Inc.	Compositions and methods for adoptive cell therapies
EP3621648A4 (fr)	2017-05-12	2021-01-20	Harpoon Therapeutics, Inc.	Protéines trispécifiques ciblant la msln et procédés d'utilisation
CN113896792B (zh)	2017-05-12	2025-08-22	哈普恩治疗公司	间皮素结合蛋白质
IL302613B2 (en)	2017-09-08	2025-04-01	Maverick Therapeutics Inc	Binding proteins are activated under limited conditions
CN111315773A (zh)	2017-09-08	2020-06-19	马弗里克治疗公司	含有Fc区的条件性活化的结合部分
KR102425983B1 (ko)	2017-10-13	2022-07-29	하푼 테라퓨틱스, 인크.	삼중특이적 단백질 및 사용 방법
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
KR102578682B1 (ko) *	2017-11-01	2023-09-13	난트바이오 인코포레이티드	Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells)
CN110218256B (zh) *	2018-03-02	2020-12-08	广西医科大学	抗CD3的纳米抗体CD3/Nb29及其制备方法与应用
CN110218253B (zh) *	2018-03-02	2020-12-04	广西医科大学	抗CD3的纳米抗体CD3/Nb14及其制备方法与应用
JP7460609B2 (ja)	2018-05-14	2024-04-02	ウェアウルフセラピューティクス，インコーポレイテッド	活性化可能なインターロイキン－２ポリペプチド及びその使用方法
KR20210020903A (ko) *	2018-05-14	2021-02-24	하푼 테라퓨틱스, 인크.	면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
US20210269530A1 (en) *	2018-05-14	2021-09-02	Harpoon Therapeutics, Inc.	Conditionally activated binding protein comprising a sterically occluded target binding domain
SG11202011308VA (en)	2018-05-14	2020-12-30	Werewolf Therapeutics Inc	Activatable cytokine polypeptides and methods of use thereof
CN112654633B (zh) *	2018-06-22	2025-05-09	科优基因公司	基于细胞因子的可生物活化药物及其使用方法
US20210309756A1 (en)	2018-08-09	2021-10-07	Maverick Therapeutics, Inc.	Coexpression and purification method of conditionally activated binding proteins
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
IL281683B2 (en)	2018-09-25	2023-04-01	Harpoon Therapeutics Inc	dll3 binding proteins and methods of use
AU2020216386A1 (en) *	2019-01-29	2021-09-16	Boehringer Ingelheim Io Canada Inc.	Multispecific binding proteins
EP4592313A3 (fr)	2019-03-05	2025-11-19	Takeda Pharmaceutical Company Limited	Protéines de liaison à activation conditionnelle restreinte
EP3934761A1 (fr)	2019-03-05	2022-01-12	Takeda Pharmaceutical Company Limited	Protéines de liaison activées de manière conditionnelle contenant des régions fc et des fractions ciblant des antigènes tumoraux
EP3969035A4 (fr)	2019-05-14	2023-06-21	Werewolf Therapeutics, Inc.	Groupes caractéristiques de séparation, procédés et utilisation associés
WO2021097060A1 (fr) *	2019-11-13	2021-05-20	Harpoon Therapeutics, Inc.	Molécule pro-immunomodulatrice comprenant une fraction de groupement
MX2022005666A (es)	2019-11-14	2022-10-07	Werewolf Therapeutics Inc	Polipeptidos de citocina activables y metodos de uso de los mismos.
CA3164353A1 (fr) *	2019-12-13	2021-06-17	Cugene Inc.	Medicaments bioactivables a base de cytokine et procedes d'utilisations associes
JP7392145B2 (ja) *	2019-12-20	2023-12-05	山東博安生物技術股▲ふん▼有限公司	免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム
CN114945597A (zh) *	2020-01-17	2022-08-26	艾提欧生物疗法有限公司	降低脱靶毒性的前抗体
KR20220150288A (ko) *	2020-01-17	2022-11-10	아에티오 바이오써래피, 인코포레이티드	오프-표적 독성을 감소시키는 프로-항체
CA3170833A1 (fr)	2020-02-21	2021-08-26	Harpoon Therapeutics, Inc.	Proteines de liaison a flt3 et methodes d'utilisation
AU2021254279A1 (en)	2020-04-09	2022-11-10	Cytomx Therapeutics, Inc.	Compositions containing activatable antibodies
WO2022002112A1 (fr)	2020-07-01	2022-01-06	Shandong Boan Biotechnology Co., Ltd.	Anticorps anti-gpc3, récepteur antigénique chimérique anti-gpc3 et anticorps bispécifique gpc3/cd3
US20240409617A1 (en)	2020-07-03	2024-12-12	Dana-Farber Cancer Institute, Inc.	Multispecific coronavirus antibodies
US20240026011A1 (en)	2020-08-17	2024-01-25	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
JP2023545347A (ja) *	2020-08-18	2023-10-30	オンチレス・ファーマ・インコーポレイテッド	改変セリンプロテアーゼプロタンパク質
JP2023550148A (ja)	2020-11-20	2023-11-30	シンシア・イノベーション・インコーポレイテッド	がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
WO2022125576A1 (fr)	2020-12-09	2022-06-16	Janux Therapeutics, Inc.	Compositions et méthodes associées à des anticorps activés par des tumeurs ciblant psma et des antigènes de cellules effectrices
AU2022255387A1 (en)	2021-04-06	2023-10-19	Takeda Pharmaceutical Company Limited	Therapeutic methods using constrained conditionally activated binding proteins
WO2022235940A1 (fr)	2021-05-06	2022-11-10	Dana-Farber Cancer Institute, Inc.	Anticorps anti-alk et leurs procédés d'utilisation
JP2024534863A (ja)	2021-08-31	2024-09-26	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	自己免疫疾患及び癌の治療のための組成物及び方法
AU2022396272A1 (en)	2021-11-24	2024-06-06	Dana-Farber Cancer Institute, Inc.	Antibodies against ctla-4 and methods of use thereof
US20250051755A1 (en)	2021-12-17	2025-02-13	Dana-Farber Cancer Institute, Inc.	Platform for antibody discovery
US20250051472A1 (en)	2021-12-17	2025-02-13	Dana-Farber Cancer Institute, Inc.	Antibodies and uses thereof
WO2024039670A1 (fr)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Anticorps anti-cldn4 et leurs méthodes d'utilisation
WO2024039672A2 (fr)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Anticorps anti-mlsn et leurs méthodes d'utilisation
WO2024104988A1 (fr) *	2022-11-15	2024-05-23	F. Hoffmann-La Roche Ag	Protéines de liaison recombinantes ayant un domaine effecteur activable
WO2025237931A1 (fr) *	2024-05-15	2025-11-20	F. Hoffmann-La Roche Ag	Protéines de liaison recombinantes avec lymphocytes t activables de manière conditionnelle et domaines effecteurs recrutant des cellules nk

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2005141512A (ru) *	2003-05-31	2007-07-20	Микромет Аг (De)	Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
EP2292664B1 (fr) *	2003-10-16	2016-11-23	Amgen Research (Munich) GmbH	Molécules des-immunisées liant le CD3 multispecifiques
US20070269422A1 (en)	2006-05-17	2007-11-22	Ablynx N.V.	Serum albumin binding proteins with long half-lives
JP5753903B2 (ja)	2010-08-24	2015-07-22	ロシュグリクアートアーゲー	活性化可能な二重特異性抗体
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
BR112013029893A2 (pt) *	2011-05-21	2017-05-30	Macrogenics Inc	molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
WO2013004607A1 (fr)	2011-07-01	2013-01-10	Bayer Intellectual Property Gmbh	Polypeptides de fusion de relaxine et leurs utilisations
EP4050027A3 (fr)	2012-02-27	2022-11-30	Ablynx N.V.	Polypeptides se liant au cx3cr1
GB201203442D0 (en)	2012-02-28	2012-04-11	Univ Birmingham	Immunotherapeutic molecules and uses
EP2820047B1 (fr)	2012-03-01	2018-04-25	Amgen Research (Munich) GmbH	Molécules de liaison à un polypeptide à longue durée de vie
US20140004121A1 (en)	2012-06-27	2014-01-02	Amgen Inc.	Anti-mesothelin binding proteins
KR102301464B1 (ko) *	2013-06-10	2021-09-14	다나-파버 캔서 인스티튜트 인크.	종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
EP3122781B1 (fr) *	2014-03-28	2020-01-01	Xencor, Inc.	Anticorps bispécifiques se liant à cd38 et cd3
WO2017087789A1 (fr) *	2015-11-19	2017-05-26	Revitope Limited	Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables
US20210309756A1 (en) *	2018-08-09	2021-10-07	Maverick Therapeutics, Inc.	Coexpression and purification method of conditionally activated binding proteins

2017
- 2017-03-08 MX MX2018010824A patent/MX2018010824A/es unknown
- 2017-03-08 IL IL261432A patent/IL261432B2/en unknown
- 2017-03-08 CN CN201780028480.4A patent/CN109071667A/zh active Pending
- 2017-03-08 AU AU2017229687A patent/AU2017229687A1/en not_active Abandoned
- 2017-03-08 EP EP17764037.2A patent/EP3426689A4/fr active Pending
- 2017-03-08 TW TW111119065A patent/TW202302631A/zh unknown
- 2017-03-08 KR KR1020187029014A patent/KR102501921B1/ko active Active
- 2017-03-08 BR BR112018068189A patent/BR112018068189A2/pt unknown
- 2017-03-08 MA MA043816A patent/MA43816A/fr unknown
- 2017-03-08 TW TW106107861A patent/TW201808990A/zh unknown
- 2017-03-08 JP JP2018547940A patent/JP7195927B2/ja active Active
- 2017-03-08 CA CA3016165A patent/CA3016165A1/fr active Pending
- 2017-03-08 KR KR1020237005284A patent/KR20230041739A/ko not_active Ceased
- 2017-03-08 WO PCT/US2017/021435 patent/WO2017156178A1/fr not_active Ceased
- 2017-03-08 SG SG11201807548SA patent/SG11201807548SA/en unknown
- 2017-10-06 US US15/727,423 patent/US20180134789A1/en not_active Abandoned
2022
- 2022-05-18 JP JP2022081366A patent/JP7293456B2/ja active Active
2023
- 2023-06-07 JP JP2023093681A patent/JP2023123519A/ja active Pending

Also Published As

Publication number	Publication date
SG11201807548SA (en)	2018-09-27
IL261432B2 (en)	2024-03-01
JP7195927B2 (ja)	2022-12-26
CN109071667A (zh)	2018-12-21
CA3016165A1 (fr)	2017-09-14
RU2018134949A3 (fr)	2020-08-14
JP7293456B2 (ja)	2023-06-19
RU2018134949A (ru)	2020-04-08
BR112018068189A2 (pt)	2019-02-05
AU2017229687A1 (en)	2018-09-20
IL261432B1 (en)	2023-11-01
WO2017156178A1 (fr)	2017-09-14
TW202302631A (zh)	2023-01-16
JP2023123519A (ja)	2023-09-05
KR20230041739A (ko)	2023-03-24
JP2019513014A (ja)	2019-05-23
US20180134789A1 (en)	2018-05-17
EP3426689A4 (fr)	2020-01-15
JP2022140856A (ja)	2022-09-28
IL261432A (en)	2018-10-31
KR20180120245A (ko)	2018-11-05
TW201808990A (zh)	2018-03-16
MX2018010824A (es)	2019-05-15
EP3426689A1 (fr)	2019-01-16
KR102501921B1 (ko)	2023-02-21

Publication	Publication Date	Title
MA43816A (fr)	2018-11-28	Protéines de liaison inductibles et méthodes d'utilisation
EP3442991A4 (fr)	2019-11-20	Peptides de liaison à ras et méthodes d'utilisation
EP3355920A4 (fr)	2019-05-15	Protéines de liaison à pd-1 et leurs méthodes d'utilisation
EP3694529A4 (fr)	2021-11-10	Protéines trispécifiques et méthodes d'utilisation
FR24C1033I2 (fr)	2025-05-23	Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
EP3802581A4 (fr)	2022-04-13	Protéines de liaison multispécifiques et améliorations de celles-ci
IL281683A (en)	2021-05-31	Dll3 binding proteins and methods of use
MA47113A (fr)	2019-10-30	Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
EP3678731A4 (fr)	2021-06-09	Soupapes hémostatiques et méthodes d'utilisation
EP3684361A4 (fr)	2021-09-08	Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
MA42925A (fr)	2018-08-01	Anticorps anti-tigit et méthodes d'utilisation
EP3429591A4 (fr)	2019-07-24	Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
IL261666A (en)	2018-10-31	Related proteins and methods of using them
EP3655432A4 (fr)	2021-04-14	Protéines de liaison 1
MA42243A (fr)	2018-05-02	Anticorps de facteur xi et méthodes d'utilisation
EP3393382A4 (fr)	2019-09-04	Couteau ophtalmique et méthodes d'utilisation
EP3317273A4 (fr)	2019-03-20	Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
EP3402549A4 (fr)	2019-09-11	Compositions pour micro-aiguilles et méthodes d'utilisation de celles-ci
EP3423451A4 (fr)	2019-09-04	Inhibiteurs de la liaison protéine wdr5-protéine
MA43387A (fr)	2018-10-10	Anticorps anti-gitr et leurs méthodes d'utilisation
MA48579A (fr)	2020-03-18	Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
EP3319611A4 (fr)	2019-03-06	Oxystérols et leurs méthodes d'utilisation
MA43385A (fr)	2018-10-10	Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA44526A (fr)	2021-06-02	Oxystérols et leurs méthodes d'utilisation
EP3426298A4 (fr)	2019-11-27	Molécules de liaison à l'ilt7 et leurs méthodes d'utilisation